Indications for: LYSTEDA

Cyclic heavy menstrual bleeding.

Adult Dosage:

Treat for up to 5 days during menses. Swallow whole. ≥18yrs: Normal renal function (serum creatinine ≤1.4mg/dL): 1300mg three times daily; Cr >1.4–2.8mg/dL: 1300mg twice daily; Cr >2.8–5.7mg/dL: 1300mg once daily; Cr >5.7mg/dL: 650mg once daily.

Children Dosage:

Premenarchal: not recommended.

LYSTEDA Contraindications:

Active thromboembolic (eg, DVT, PE, cerebral thrombosis). History or risk of thrombosis or thromboembolism (eg, retinal vein or artery occlusion; thrombogenic valvular disease, thrombogenic cardiac rhythm disease, hypercoagulopathy). Concomitant combination hormonal contraceptives.

LYSTEDA Warnings/Precautions:

Exclude endometrial pathology prior to initiation. Not for use in postmenopausal women. Discontinue immediately if retinal venous or arterial occlusion occurs. Subarachnoid hemorrhage (cerebral edema/infarction may occur). Acute promyelocytic leukemia treated with oral tretinoin (increased procoagulant effect). Renal impairment. Pregnancy. Nursing mothers.

LYSTEDA Classification:


LYSTEDA Interactions:

See Contraindications: for hormonal contraceptives. Increased risk of thrombotic events with Factor IX complex concentrates, anti-inhibitor coagulant concentrates, oral tretinoin: use not recommended. Tissue plasminogen activators (tPAs) may decrease efficacy of both tranexamic acid and tPAs.

Adverse Reactions:

Headache, sinus/nasal symptoms, pain (back, abdomen, musculoskeletal, joint), muscle cramps, migraine, anemia, fatigue; visual/ocular events, severe allergic reaction, ligneous conjunctivitis.

Generic Drug Availability:


How Supplied: